Literature DB >> 8813263

Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin.

J L Grosfeld1, M Chaet, F Molinari, W Engle, S A Engum, K W West, F J Rescorla, L R Scherer.   

Abstract

OBJECTIVE: The authors evaluated the risk of necrotizing enterocolitis (NEC) in very low birth weight infants receiving indomethacin (INDO) to close patent ductus arteriosus (PDA). BACKGROUND DATA: Controversy exists regarding the best method of managing very low birth weight infants with PDA and whether to employ medical management using INDO or surgical ligation of the ductus.
METHODS: Two hundred fifty-two premature infants with symptomatic PDA were given intravenously INDO 0.2 mg/kg every 12 hours x 3 in an attempt to close the ductus. Patients were evaluated for sex, birth weight, gestational age, ductus closure, occurrence of NEC, bowel perforation, and mortality.
RESULTS: There were 135 boys and 117 girls. The PDA closed or became asymptomatic in 224 cases (89%), whereas 28 (11%) required surgical ligation. Ninety infants (35%) developed evidence of NEC after INDO therapy. Fifty-six were managed medically; surgical intervention was required in 34 of 90 cases (37.8%) or 13% of the entire PDA/INDO study group. Bowel perforation was noted in 27 cases (30%). Factors associated with the onset of NEC included gestational age < 28 weeks, birth weight < 1 kg, and prolonged ventilator support. The overall mortality rate was 25.5%, but was higher in infants with NEC versus those without. The highest mortality was noted in perforated NEC cases. The PDA/INDO patients were compared with a control group of 764 infants with similar sex distribution, birth weights, and gestational ages without PDA who did not receive INDO. Necrotizing enterocolitis occurred in 105 of 764 control patients (13.7%), including 13 (12.3%) with perforation. The overall mortality rate of controls was 25%, which was similar to the overall 25.5% mortality rate in the PDA/INDO study group.
CONCLUSION: These data indicate that there is increased risk of NEC and bowel perforation in premature infants with PDA receiving INDO. Mortality was higher in the PDA/INDO group with NEC than those PDA/INDO infants without NEC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813263      PMCID: PMC1235380          DOI: 10.1097/00000658-199609000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Localized intestinal perforations after enteral administration of indomethacin in premature infants.

Authors:  G Alpan; F Eyal; I Vinograd; R Udassin; G Amir; P Mogle; B Glick
Journal:  J Pediatr       Date:  1985-02       Impact factor: 4.406

2.  Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding.

Authors:  M M Eibl; H M Wolf; H Fürnkranz; A Rosenkranz
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

3.  Hemodynamically significant PDA: an echocardiographic and clinical assessment of incidence, natural history, and outcome in very low birth weight infants maintained in negative fluid balance.

Authors:  M D Reller; J M Lorenz; U R Kotagal; R A Meyer; S Kaplan
Journal:  Pediatr Cardiol       Date:  1985       Impact factor: 1.655

4.  Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants.

Authors:  L Mahony; V Carnero; C Brett; M A Heymann; R I Clyman
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

5.  Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen.

Authors:  F Coceani; E White; E Bodach; P M Olley
Journal:  Can J Physiol Pharmacol       Date:  1979-08       Impact factor: 2.273

6.  Management of patent ductus arteriosus in the premature infant: indomethacin versus ligation.

Authors:  C Mavroudis; L N Cook; J W Fleischaker; H S Nagaraj; R J Shott; W R Howe; L A Gray
Journal:  Ann Thorac Surg       Date:  1983-11       Impact factor: 4.330

7.  Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia.

Authors:  J L Grosfeld; K Kamman; K Gross; D Cikrit; D Ross; M Wolfe; S Katz; T R Weber
Journal:  J Pediatr Surg       Date:  1983-12       Impact factor: 2.545

8.  Intestinal perforation associated with indomethacin treatment in premature infants.

Authors:  G Kühl; L Wille; M Bolkenius; H W Seyberth
Journal:  Eur J Pediatr       Date:  1985-01       Impact factor: 3.183

9.  The protective role of enteral IgA supplementation in neonatal gut origin sepsis.

Authors:  R T Maxson; R J Jackson; S D Smith
Journal:  J Pediatr Surg       Date:  1995-02       Impact factor: 2.545

10.  Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.

Authors:  W M Gersony; G J Peckham; R C Ellison; O S Miettinen; A S Nadas
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

View more
  36 in total

1.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2019-06-21

2.  Neonatal colour Doppler ultrasound study: normal values of abdominal blood flow velocities in the neonate during the first month of life.

Authors:  Patrizia Papacci; Carmen Giannantonio; Francesco Cota; Caterina Latella; Carla Maria Semeraro; Maria Fioretti; Mikael Ghennet Tesfagabir; Costantino Romagnoli
Journal:  Pediatr Radiol       Date:  2009-02-03

Review 3.  A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.

Authors:  Ronald L Thomas; Graham C Parker; Bart Van Overmeire; Jacob V Aranda
Journal:  Eur J Pediatr       Date:  2004-12-10       Impact factor: 3.183

4.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-01-27

5.  Temporal and seasonal variations in incidence of stage II and III NEC-a 28-year epidemiologic study from tertiary NICUs in Connecticut, USA.

Authors:  Darius Javidi; Zigeng Wang; Sanguthevar Rajasekaran; Naveed Hussain
Journal:  J Perinatol       Date:  2021-02-15       Impact factor: 2.521

Review 6.  Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Manoj N Malviya; Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

7.  Pharmacoeconomics of Surgical Interventions vs. Cyclooxygenase Inhibitors for the Treatment of Patent Ductus Arteriosus.

Authors:  Charles J Turck; Wallace Marsh; James G Stevenson; John M York; Henry Miller; Snehal Patel
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

8.  Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

Authors:  Karen E Corff; Kris C Sekar
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

Review 9.  Pathogenesis of neonatal necrotizing enterocolitis.

Authors:  Joanna C Lim; Jamie M Golden; Henri R Ford
Journal:  Pediatr Surg Int       Date:  2015-04-09       Impact factor: 1.827

10.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.